ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
Achilles Therapeutics PLC

Achilles Therapeutics PLC (ACHL)

1.07
0.02
(1.90%)
終了 11月21日 6:00AM
1.07
0.00
( 0.00% )
プレマーケット: 6:00PM

個人投資家向けのプロ仕様のツール。

主要統計と詳細

通貨
1.07
買値
1.01
売値
1.07
出来高
-
0.00 日の範囲 0.00
0.00 52 週間の範囲 0.00
時価総額
前日終値
1.07
始値
-
時刻
最終取引時間
-
財務取引量
-
VWAP
-
平均取引量 (3 か月)
-
発行済株式数
41,082,948
配当利回り
-
PER
0.00
1 株当たり利益 (EPS)
-
歳入
6.08M
純利益
-69.67M

Achilles Therapeutics PLC について

Achilles Therapeutics PLC is a biopharmaceutical company. It is developing novel cancer immunotherapies targeting clonal neoantigens. The company has two ongoing trials, the CHIRON trial in patients with advanced non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastati... Achilles Therapeutics PLC is a biopharmaceutical company. It is developing novel cancer immunotherapies targeting clonal neoantigens. The company has two ongoing trials, the CHIRON trial in patients with advanced non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma. 詳細を表示

セクター
Pharmaceutical Preparations
業界
Pharmaceutical Preparations
ウェブサイト
本社
London, Gbr
設立
-
Achilles Therapeutics PLC is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker ACHL. The last closing price for Achilles Therapeutics was US$1.07. Over the last year, Achilles Therapeutics shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Achilles Therapeutics currently has 41,082,948 shares in issue. The market capitalisation of Achilles Therapeutics is US$43.96 million.

ACHL 最新ニュース

Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market

LONDON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced that on November 15, 2024, the Listing Qualifications department of the Nasdaq Stock Market...

Achilles Therapeutics Reports Third Quarter 2024 Financial Results

– Cash position of $86.1 million as of September 30, 2024, not including cash R&D tax credit of $12.8 million received in October 2024 –         LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE...

Achilles Therapeutics Announces Strategic Update

–Achilles to discontinue development of TIL-based cNeT therapy– –Cash position of $95.1 million as of June 30, 2024– –BofA Securities engaged to provide strategic financial advice–        ...

Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates

– Announced research collaboration with Arcturus Therapeutics to explore second-generation mRNA cancer vaccines using Achilles’ AI-powered, tumor-targeting technology – – Provided interim Phase...

Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines

Combines Achilles’ best-in-class AI-driven, tumor-targeting technology with Arcturus’ world-leading self-amplifying mRNA platform Combined technologies have the potential to generate potent and...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
WORXSCWorx Corporation
US$ 1.94
(97.96%)
11.68M
PETWag Group Company
US$ 0.338
(60.88%)
13.47M
VEEAVeea Inc
US$ 3.96
(40.43%)
2.71M
AKTSAkoustis Technologies Inc
US$ 0.1201
(37.89%)
23.29M
CCECCapital Clean Energy Carriers Corporation
US$ 24.99
(34.72%)
2
WSBFWaterstone Financial Inc
US$ 9.00
(-40.98%)
4
TRSTriMas Corporation
US$ 15.62
(-40.79%)
1
BCAXBicara Therapeutics Inc
US$ 11.00
(-40.15%)
104
XNCRXencor Inc
US$ 15.11
(-36.30%)
2
HSTMHealthStream Inc
US$ 20.00
(-36.10%)
102
AKTSAkoustis Technologies Inc
US$ 0.1201
(37.89%)
23.29M
PETWag Group Company
US$ 0.338
(60.88%)
13.47M
WORXSCWorx Corporation
US$ 1.94
(97.96%)
11.68M
XTKGX3 Holdings Company Ltd
US$ 0.0832
(-7.56%)
9.93M
ELABElevai Labs Inc
US$ 0.0207
(-3.27%)
2.92M

ACHL Discussion

投稿を表示